Opinion|Videos|April 1, 2026
Building Upon the Lenalidomide/Rituximab Backbone in R/R Follicular Lymphoma
Author(s)Loretta J. Nastoupil, MD, Amitkumar Mehta, MD
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss methods of building on the lenalidomide/rituximab backbone in relpased/refractory follicular lymphoma.
Advertisement
Episodes in this series
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss how the lenalidomide/rituximab (R²) backbone continues to serve as a foundation for novel combination strategies in relapsed/refractory follicular lymphoma. Nastoupil reviews the clinical impact of adding agents such as tafasitamab to R² and how recent approvals are shaping practice. Mehta underscores how updated NCCN Guidelines and emerging triplet regimens are influencing second-line treatment decision-making.
Advertisement
Related to this article
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
5